Pegfilgrastim administered on the same day with Dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: Matched Case-control study of the hellenic cooperative oncology group

Oncology

Volumn 77, Issue 2, 2008, Pages 107-112

  Skarlos, Dimosthenis V ^a   Timotheadou, Eleni ^b   Galani, Eleni ^a   Samantas, Epaminondas ^c   Grimani, Irene ^d   Lianos, Evangelos ^e   Aravantinos, Gerasimos ^c   Xanthakis, Ioannis ^b   Pentheroudakis, George ^f   Pectasides, Dimitrios ^g   Fountzilas, George ^b  

^a Department of Medical   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d Hellenic Cooperative Oncology Group   (Greece)

^e ALEXANDRA HOSPITAL   (Greece)

^f UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; Dose dense chemotherapy; Febrile neutropenia; Pegfilgrastim

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; FILGRASTIM; HUMANS; INCIDENCE; MIDDLE AGED; NEUTROPENIA;

EID: 67650702947     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229504     Document Type: Article

References (19)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulated leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-346.
2. Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metcalf D, Fox R: Effect of granulocyte colony stimulating factor on neutropenia induced by cy-totoxic chemotherapy. Lancet 1988;i:667-672. (Pubitemid 18083268)
3. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group: a randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
4. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher FA, Cohen A, Korach E, Ulich T, McNiece I, Lockbaum P, Miller-Messana MA, Gardner S, Hunt T, Schwab G: A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize RBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
5. Schippinger W, Holub R, Dandachi N, Bau-ernhofer T, Samonigg H: Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitax-el with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim. Oncology 2006; 70: 290-293.
6. Kuderer NM, Dale DC, Crawford J, Lyman GH: Impact of primary prophylaxis with granulocyte colony stimulation factors of febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25: 3158-3165.
7. Mamounas EP, Bryant J, Lembersky B, Feh-renbacher L, Sedlacek SM, Fisher B, Wicher-ham DL, Yothers G, Soran A, Wolmark N: Paclitaxel after doxorubicin plus cyclophos-phamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696.
8. Norton L, Simon R: The Norton-Simon hypothesis revised. Cancer Treat Rep 1986; 70-163.
9. Citron M, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adju-vant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
10. Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM: Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992; 84: 1201-1203.
11. Hoffmann PS: Administration of pegfilgras-tim on the same day or next day of chemotherapy. 2005 ASCO Annu Meet Proc. J Clin Oncol 2005; 23(suppl16S):8137.
12. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Sa-mantas E, Bafaloukos D, Stathopoulos GP, Karina M, Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C, Tzorakoeleftherakis E, Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A, Varthalitis I, Karanikiotis C, Dimopoulos AM, Hellenic Cooperative Oncology Group: Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol 2008; 19: 853-860. (Pubitemid 351649185)
13. Fountzilas G, Pectasides D, Christodoulou C, Timotheadou E, Economopoulos T, Papa-kostas P, Papadimitriou C, Gogas H, Efstra-tiou I, Skarlos D: Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol 2006; 23: 479-488.
14. Snedecor G, Cochran W (eds): Statistical Methods. Ames, Iowa State University Press, 1980.
15. Zar JH: Biostatistical Analysis. Englewood Cliffs, Prentice-Hall, 1984.
16. Holmes FA, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC: Blinded, randomized, multi-center study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III-IV breast cancer. J Clin Oncol 2002; 20: 727-731.
17. Yardley DA, Greco FA, Burris HA, et al: Day 1 pegfilgrastim with dose-dense adjuvant chemotherapy: amelioration of docetaxel neutropenia, but not that of doxorubicin/cy-clophosphamide. Results from a Sarah Cannon Research Institute Pilot Study. 2005 ASCO Annu Meet Proc. J Clin Oncol 2005; 23(suppl16S):749.
18. Saven A, Schwartzberg L, Kaywin P, et al: Randomized, double blind phase II study evaluated same-day vs. next-day administration of pegfilgrastim with R-CHOP in non-ASCO Annu Meet Proc. J Clin Oncol 2006; 24(suppl18S):7570.
19. Belani CP, Ramalingam S, Al-Janati A, et al: A randomized, double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with non-small cell lung cancer. 2006 ASCO Annu Meet Proc. J Clin Oncol 2006; 24(suppl18S):749.